What Is HGH Fragment 176-191? Benefits, Research & Safety
A fragment of human growth hormone corresponding to amino acids 176-191, researched specifically for its fat-metabolising properties.
UK summary: Not a licensed UK medicine. C-terminal fragment of growth hormone marketed for selective fat loss. Conceptually distinct from full HGH but still captured by WADA growth-factor rules. Human evidence is weak.
Quick Facts
Overview
HGH Fragment 176-191 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. C-terminal fragment of growth hormone marketed for selective fat loss. Conceptually distinct from full HGH but still captured by WADA growth-factor rules. Human evidence is weak.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for human therapeutic use.
- Notes: HGH Fragment 176-191 is not approved by any regulatory authority for human use. It is available only as a research chemical.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Targeted fat-loss without affecting muscle, glucose, or growth.
- Stack safely with semaglutide for accelerated body recomposition.
- FDA / MHRA approved as a 'safe' alternative to HGH.
- Suitable for daily long-term home injection.
07Common internet claims
- Marketed as the lipolytic fragment of HGH for cosmetic fat loss.
- Sold by online retailers as 'HGH frag' alongside AOD-9604.
- Promoted in bodybuilding cut-cycle stacks.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Burns fat without HGH side effects” | D | Limited | High | Animal-model lipolytic effect is documented; meaningful human body-composition outcomes are not established. |
| “Permitted in sport (it's only a fragment)” | E | No | High | Prohibited under WADA growth-factors category; strict liability applies. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Injection-site reactions.
- Headache, fatigue, nausea reported anecdotally.
- Theoretical risk from chronic GH-fragment exposure (fluid retention, organ growth).
- Unknown effects in combination with licensed GLP-1 medicines.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
14EU legal position
Not approved for human therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased vial actually contains HGH Fragment 176-191 at the labelled concentration.
- Whether the AOD-9604 variant (which has a tyrosine on the N-terminus) is in the vial instead.
- What clinically meaningful fat-loss effect (if any) it has in normal-weight adults.
- What the WADA in-competition exposure looks like — growth-factor peptides are class-prohibited.
16Last reviewed
17Citation quality score
18Research gaps
- No published Phase 3 trials in healthy adults for cosmetic fat loss.
- Long-term safety beyond a few weeks is unstudied.
- Combination safety with GLP-1 agonists not assessed.
- Human pharmacokinetic data is sparse.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) via NHS or GMC-registered prescriber.
- Licensed Mounjaro (tirzepatide) via NHS specialist or registered private clinic.
- Structured diet, resistance training, and cardio — the evidence-based body-recomposition stack.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is HGH Fragment 176-191 a licensed UK medicine?
- What are the WADA / UKAD anti-doping implications?
- What licensed alternatives exist for fat-loss support?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Stimulation of fat breakdown without affecting muscle tissue
- 2Inhibition of new fat formation
- 3No significant effect on blood glucose in studies
- 4No stimulation of IGF-1 production
- 5No growth-promoting effects observed
- 6Potential for targeted fat reduction
Claim vs Evidence
How popular claims about HGH Fragment 176-191 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Burns fat without HGH side effects” | D | Limited | High | Animal-model lipolytic effect is documented; meaningful human body-composition outcomes are not established. |
| “Permitted in sport (it's only a fragment)” | E | No | High | Prohibited under WADA growth-factors category; strict liability applies. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 250-500 mcg per administration (based on research protocols) |
| Frequency | 1-2 times daily, typically before cardio exercise |
| Duration | Variable in research settings; typically weeks to months |
| Notes | These are theoretical protocols derived from research literature. HGH Fragment 176-191 is not approved for human use. Any consideration of use should involve consultation with a qualified healthcare professional. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
| Half-Life | Stability |
|---|---|
| Short; approximately 30 minutes to a few hours | Lyophilised powder should be stored frozen; reconstituted solution refrigerated |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions
- Potential hypoglycaemia if used with insulin (theoretical)
- Headache (reported anecdotally)
Rare Risks & Concerns
- Long-term effects unknown in humans
- Potential for contamination in non-pharmaceutical grade products
- Effects on other metabolic parameters not fully characterised
Contraindications
- Pregnancy and breastfeeding
- Active malignancy
- Diabetes (use with caution)
- Children and adolescents
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for human therapeutic use.
Clinical Studies Summary
Lipolytic Activity of a Human Growth Hormone Fragment
Preclinical research demonstrating the fat-metabolising activity of the 176-191 fragment of human growth hormone.
Looking for HGH Fragment 176-191?
Source research-grade HGH Fragment 176-191 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about HGH Fragment 176-191
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is HGH Fragment 176-191 a licensed UK medicine?
- What are the WADA / UKAD anti-doping implications?
- What licensed alternatives exist for fat-loss support?
UK regulatory & safety context
Related Research Guides
Related Peptides
AOD-9604
A modified fragment of human growth hormone specifically researched for its fat-metabolising properties without the growth-promoting effects of full HGH.
Learn moreCJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn more